Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?

abstract：:Lymphocytes regenerated after treatment with a high dose of cyclophosphamide (CY) were characterized in nude mice. Ten days after a single injection of 200 mg/kg CY into nude mice, regenerated spleen cells suppressed in vitro primary and second antibody production against sheep red blood cells. The CY-treated spleen c...

journal_title：Anti-cancer drugs

authors： Shimizu M,Sabolovic D,Ozawa H,Iwaguchi T

更新日期：1992-08-01 00:00:00

abstract：:Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicab...

journal_title：Anti-cancer drugs

authors： Myc A,Douce TB,Ahuja N,Kotlyar A,Kukowska-Latallo J,Thomas TP,Baker JR Jr

更新日期：2008-02-01 00:00:00

abstract：:Octreotide appears to have a major therapeutic effect in the management of diarrhoea related to cancer therapy. This effect is seen in the acute diarrhoea following radiation therapy and chemotherapy, and also in late radiation enteritis. As well as providing improved symptom control, early treatment can prevent poten...

journal_title：Anti-cancer drugs

authors： Baillie-Johnson HR

更新日期：1996-01-01 00:00:00

abstract：:Numerous reports on colon carcinogenesis reveal gender differences in the incidence and location of tumors. A large number of the presented studies suggest that sex-steroids have a considerable effect on tumorigenesis of the large bowel. To clarify the, so far, not fully understood mechanisms and somewhat conflicting ...

journal_title：Anti-cancer drugs

authors： Dornschneider G,Izbicki JR,Wilker DK,Schweiberer L

更新日期：1990-10-01 00:00:00

abstract：:Silibinin, with a strong antioxidant activity and a weak cytotoxic property, is considered a candidate for cancer prevention. As there is no information on its effect on breast cancer tumor-initiating cells [cancer stem cells (CSCs)] in a 3D culture model, which more closely mimic natural tissues, we carried out this ...

journal_title：Anti-cancer drugs

authors： Abdollahi P,Ebrahimi M,Motamed N,Samani FS

更新日期：2015-06-01 00:00:00

abstract：:Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial...

journal_title：Anti-cancer drugs

authors： West CM,Price P

更新日期：2004-03-01 00:00:00

abstract：:This study was performed to evaluate the role of protein kinase C (PKC) activity in the development of chemoresistance in clinical breast cancer cells. To simulate the clinical situation, native tumor cells derived from 10 patients with advanced breast cancer were brought into short-term cultures, and treated with ant...

journal_title：Anti-cancer drugs

authors： Schöndorf T,Hoopmann M,Breidenbach M,Rein DT,Göhring UJ,Becker M,Mallmann P,Kurbacher CM

更新日期：2004-03-01 00:00:00

abstract：:Declopramide (3-chloroprocainamide) has been identified in previous studies as a representative of a new class of chemosensitizers. In this study, the toxicity and pharmacokinetics of declopramide have been investigated and compared with a structural analog, metoclopramide (MCA). Declopramide has not induced central n...

journal_title：Anti-cancer drugs

authors： Hua J,Pero RW,Kane R

更新日期：1999-01-01 00:00:00

abstract：:Response rates reported in early phase II clinical trials are often not reproduced in subsequent larger or phase III studies. Independent review of claimed partial or complete responders to gemcitabine was undertaken in four pivotal, open-label phase II studies of advanced, non-small cell lung cancer (NSCLC) to provid...

journal_title：Anti-cancer drugs

authors： Gwyther SJ,Aapro MS,Hatty SR,Postmus PE,Smith IE

更新日期：1999-09-01 00:00:00

abstract：:Results from our previous phase II study demonstrating high efficacy and low toxicity for a weekly schedule of 5-fluorouracil (5-FU)/leucovorin in intensively pretreated patients with metastatic breast cancer prompted addition of paclitaxel and cisplatin to this regimen for a phase II study of outpatient first-line tr...

journal_title：Anti-cancer drugs

authors： Klaassen U,Wilke H,Weyhofen R,Harstrick A,Eberhardt W,Müller C,Korn M,Hanske M,Diergarten K,Seeber S

更新日期：1998-03-01 00:00:00

abstract：:Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme with a role in the maintenance of DNA topology. Topo IIalpha is a target for several anticancer drugs and the levels of activity of this enzyme have been implicated in the development of drug resistance. Our objective was to identify regulatory transc...

journal_title：Anti-cancer drugs

authors： Allen KA,Williams AO,Isaacs RJ,Stowell KM

更新日期：2004-04-01 00:00:00

abstract：:Cancer stem cells play a fundamental role in the growth, metastasis, recurrence, and chemoresistance of cancers of various origins; therefore, targeting these cells may prospectively help to eradicate cancer cells from patients. In this study, the effect of tetrandrine on the proliferation of CD133-positive (CD133) He...

journal_title：Anti-cancer drugs

authors： Cui X,Xiao D,Wang X

更新日期：2019-10-01 00:00:00

abstract：:The primary aim of this randomized trial was to determine response rate and progression-free survival following chemotherapy in patients with platinum-resistant recurrent ovarian cancer, who had been treated according to an ATP-based tumour chemosensitivity assay in comparison with physician's choice. A total of 180 p...

journal_title：Anti-cancer drugs

authors： Cree IA,Kurbacher CM,Lamont A,Hindley AC,Love S,TCA Ovarian Cancer Trial Group.

更新日期：2007-10-01 00:00:00

abstract：:ET-743 is a marine anti-cancer drug and is currently in phase I trials in which the effect of combination therapies will be investigated. Its dose-limiting toxicity in patients is hepatotoxicity. In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and ...

journal_title：Anti-cancer drugs

authors： Brandon EF,Meijerman I,Klijn JS,den Arend D,Sparidans RW,Lázaro LL,Beijnen JH,Schellens JH

更新日期：2005-10-01 00:00:00

abstract：:This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting toxicity (DLT) was considered to be any grade greater than or equal to 3 (G> or =3) nonhemat...

journal_title：Anti-cancer drugs

authors： Briasoulis E,Golfinopoulos V,Karina M,Papakostas P,Pavlidis N,Fountzilas G

更新日期：2010-09-01 00:00:00

abstract：:We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC). In this study, we added mitomycin (MMC) to 5-FU and LV in an attempt to improve the response rate and surviv...

journal_title：Anti-cancer drugs

authors： Chen JS,Lin YC,Jan YY,Liau CT

更新日期：2001-04-01 00:00:00

abstract：:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

journal_title：Anti-cancer drugs

authors： Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

更新日期：2007-01-01 00:00:00

abstract：:Gastrointestinal stromal tumors (GIST) are the most common malignant mesenchymal tumors of the gastrointestinal tract. The principal treatment modality for primary GIST is surgery whereas for metastatic GIST, imatinib has an established role. In patients with locally advanced and metastatic GIST, the role of surgery i...

journal_title：Anti-cancer drugs

authors： Mearadji A,den Bakker MA,van Geel AN,Eggermont AM,Sleijfer S,Verweij J,de Wilt JH,Verhoef C

更新日期：2008-07-01 00:00:00

abstract：:The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on...

journal_title：Anti-cancer drugs

authors： Caballero Romero Á,Delgado Ureña MT,Salmerón García A,Megías Fernández MT,Librada Porriño-Bustamante M,Cabeza Barrera J

更新日期：2018-10-01 00:00:00

abstract：:CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. In this study the fluorometric microculture cytotoxicity assay was used for evaluation of CHS 828 in primary...

journal_title：Anti-cancer drugs

authors： Frost BM,Lönnerholm G,Nygren P,Larsson R,Lindhagen E

更新日期：2002-08-01 00:00:00

abstract：:Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a hig...

journal_title：Anti-cancer drugs

authors： Pointreau Y,Atean I,Fayette J,Calais G,Lefebvre JL

更新日期：2011-08-01 00:00:00

abstract：:To evaluate the feasibility and pharmacology of intrapleural (IP(L)) administration of paclitaxel, 18 patients with malignant pleural effusions were entered onto a phase I clinical study, 13 were caused by lung cancer. Following an effusion drainage rate of less than 100 ml/24 h and full expansion of the lung, patient...

journal_title：Anti-cancer drugs

authors： Perng RP,Wu MF,Lin SY,Chen YM,Lin JY,Whang-Peng J

更新日期：1997-07-01 00:00:00

abstract：:We have established estrogen-independent and antiestrogen-resistant cell lines from hormone-dependent MCF-7 breast cancer cells by long-term culture in the absence of estrogen, or in the presence of antiestrogen toremifene, respectively. By using a cDNA microarray we compared gene expression profiles among estrogen-in...

journal_title：Anti-cancer drugs

authors： Pennanen PT,Sarvilinna NS,Ylikomi TJ

更新日期：2009-01-01 00:00:00

abstract：:Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers. Lipoplatin has eliminated or reduced the systemic toxicity frequently seen for cisplatin. The objective of the present study was to determine whether the cytotoxic effect of lipoplatin is depe...

journal_title：Anti-cancer drugs

authors： Fedier A,Poyet C,Perucchini D,Boulikas T,Fink D

更新日期：2006-03-01 00:00:00

abstract：:Glioma is a primary intracranial malignant tumor with poor prognosis. In this study, we aimed to develop transferrin (Tf)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles to deliver temozolomide (TMZ) to glioma and evaluate their efficacy to kill glioma. TMZ-loaded nanoparticles were prepared by nanoprecipi...

journal_title：Anti-cancer drugs

authors： Mao J,Meng X,Zhao C,Yang Y,Liu G

更新日期：2019-07-01 00:00:00

abstract：:The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after...

journal_title：Anti-cancer drugs

authors： Inoue T,Yang DJ,Wallace S,Cherif A,Tansey W,Kim EE,Hunter N,Milross CG,Milas L,Podoloff DA

更新日期：1996-11-01 00:00:00

abstract：:Multi-targeted antifolate (MTA) is an anti-metabolite with useful activity in the treatment of non-operable patients presenting with non-small cell lung cancer. Its good efficacy and tolerability profile as first-line therapy was demonstrated in phase II studies of MTA as monotherapy. The use of MTA as second-line the...

journal_title：Anti-cancer drugs

authors： Le Chevallier T

更新日期：2001-07-01 00:00:00

abstract：:Hepatic and peritoneal metastases are the most frequent metastatic lesions in patients with gastrointestinal stromal tumors (GIST), and may result in intra- or extrahepatic cholestasis and altered drug metabolism. While the tyrosine kinase inhibitor imatinib, which has been recently shown to represent the treatment of...

journal_title：Anti-cancer drugs

authors： Bauer S,Hagen V,Pielken HJ,Bojko P,Seeber S,Schütte J

更新日期：2002-09-01 00:00:00

abstract：:Antibody-cytokine fusion proteins (also called 'immunocytokines') represent an emerging class of biopharmaceutical products, which are being considered for cancer immunotherapy. When used as single agents, pro-inflammatory immunocytokines are rarely capable of inducing complete and durable cancer regression in mouse m...

journal_title：Anti-cancer drugs

authors： Corbellari R,Nadal L,Villa A,Neri D,De Luca R

更新日期：2020-09-01 00:00:00

abstract：:BPR0C305 is a novel N-substituted indolyl glyoxylamide previously reported with in-vitro cytotoxic activity against a panel of human cancer cells including P-gp-expressing multiple drug-resistant cell sublines. The present study further examined the underlying molecular mechanism of anticancer action and evaluated the...

journal_title：Anti-cancer drugs

authors： Li WT,Yeh TK,Song JS,Yang YN,Chen TW,Lin CH,Chen CP,Shen CC,Hsieh CC,Lin HL,Chao YS,Chen CT

更新日期：2013-11-01 00:00:00